Center for Infectiology (CIB), Berlin, Germany.
Chelsea and Westminster Hospital, London, United Kingdom.
J Hepatol. 2017 Feb;66(2):282-287. doi: 10.1016/j.jhep.2016.09.004. Epub 2016 Sep 17.
BACKGROUND & AIMS: Moderate cure rates of acute hepatitis C virus (HCV) infections with pegylated interferon and ribavirin have been described in the last decade in men who have sex with men (MSM), who are also coinfected with the human immunodeficiency virus (HIV). However, a subsequent high incidence of HCV reinfections has been reported regionally in men who both clear the infection spontaneously or who respond to treatment.
Retrospective analysis of reinfections in HIV infected MSM in eight centers from Austria, France, Germany, and the UK within the NEAT network between May 2002 and June 2014.
Of 606 individuals who cleared HCV spontaneously or were successfully treated, 149 (24.6%) presented with a subsequent HCV reinfection. Thirty out of 70 (43%) who cleared again or were successfully treated, presented with a second reinfection, 5 with a third, and one with a fourth reinfection. The reinfection incidence was 7.3/100 person-years (95% CI 6.2-8.6). We found a trend for lower incidence among individuals who had spontaneously cleared their incident infection than among individuals who were treated (Hazard ratio 0.62, 95% CI 0.38-1.02, p=0.06). Spontaneous clearance of reinfection was associated with ALT levels >1000IU/ml and spontaneous clearance of a prior infection.
HCV reinfection is an issue of major concern in HIV-positive MSM. Prevention strategies are needed for high risk groups to reduce morbidity and treatment costs. HIV-positive MSM with a prior HCV infection should be tested every 3 to 6months for reinfection. Those who had achieved a reinfection should be tested every 3months.
We evaluated the occurrence of HCV reinfection in HIV-positive men who have sex with men. We found an alarming incidence of 7.3/100 person-years. Prevention measures need to address this specific subgroup of patients at high risk for HCV.
在过去十年中,接受聚乙二醇干扰素和利巴韦林治疗的男男性行为者(MSM)中的急性丙型肝炎病毒(HCV)感染者的治愈率有所提高,这些患者同时也感染了人类免疫缺陷病毒(HIV)。然而,在该地区,曾自发清除 HCV 感染或对治疗有反应的 MSM 中,已报告 HCV 再感染的发生率较高。
对 2002 年 5 月至 2014 年 6 月期间,奥地利、法国、德国和英国的 8 个中心的 NEAT 网络内的 HIV 感染 MSM 中 HCV 再感染患者进行回顾性分析。
在 606 例自发清除 HCV 或经成功治疗的患者中,149 例(24.6%)出现了 HCV 再感染。30 例(43%)再次清除或经成功治疗的患者出现了第二次再感染,5 例出现了第三次,1 例出现了第四次再感染。再感染的发生率为 7.3/100 人年(95%CI 6.2-8.6)。我们发现,与接受治疗的患者相比,自发清除初发感染的患者再感染发生率较低(风险比 0.62,95%CI 0.38-1.02,p=0.06)。再感染的自发清除与 ALT 水平>1000IU/ml 和初发感染的自发清除有关。
HCV 再感染是 HIV 阳性 MSM 中的一个主要问题。需要为高危人群制定预防策略,以降低发病率和治疗费用。有 HCV 既往感染史的 HIV 阳性 MSM 应每 3 至 6 个月检测一次再感染。对于已发生再感染的患者,应每 3 个月检测一次。
我们评估了 HIV 阳性男男性行为者中 HCV 再感染的发生情况。我们发现,再感染的发生率高达 7.3/100 人年,令人震惊。预防措施需要针对 HCV 高危特定亚组患者。